Welcome to our dedicated page for NewAmsterdam Pharma Company N.V SEC filings (Ticker: NAMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NewAmsterdam Pharma Company N.V. filings document a late-stage clinical biopharmaceutical issuer developing oral, non-statin therapies for cardiovascular-risk patients with elevated LDL-C. Its Form 8-K reports furnish financial results, corporate updates, investor presentations and clinical-program disclosures involving obicetrapib, including its use alone and with ezetimibe.
The company’s SEC record also covers proxy governance, executive compensation, equity awards, director and officer matters, compensatory arrangements and Nasdaq-listed securities. Cover-page disclosures identify ordinary shares under NAMS and warrants under NAMSW, while material-event filings record Regulation FD presentations, leadership-related agreements and public-company capital-structure information.
NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer, Louise Frederika Kooij, reported multiple option exercises and share sales in January 2026. On January 23, 2026, she exercised options for 38,172 ordinary shares at an exercise price of $10.90 per share, then sold 25,405 shares at a weighted average price of $33.44 and 12,767 shares at a weighted average price of $34.37, all as ordinary shares.
On January 26, 2026, she exercised additional options for 34,400 ordinary shares at $10.90 per share and sold 34,091 shares at a weighted average price of $32.77 and 309 shares at a weighted average price of $33.45. After these transactions, she directly owned 24,353 ordinary shares and held 145,562 options (right to buy) for ordinary shares.
NewAmsterdam Pharma Co N.V.’s Chief Financial Officer, Mayur Ian Somaiya, reported stock option exercises and related share sales. On January 20 and 21, 2026, he exercised options to acquire 60,216 and 39,784 ordinary shares at an exercise price of $9.26 per share. On the same dates, he sold several blocks of ordinary shares, including 39,712, 19,604, and 24,362 shares at prices referenced in ranges from about $30.17 to $34.31 per share, as detailed in the footnotes.
After these transactions, Somaiya directly held 58,382 ordinary shares and 662,814 option-based derivative securities. The filing states that at least one sale transaction was carried out under a Rule 10b5-1 trading plan, and notes that the underlying option was granted on November 1, 2023 with vesting over four years, subject to continued service.
NAMS reported that an affiliated holder has filed a Rule 144 notice to sell 200,000 ordinary shares through J.P. Morgan Securities LLC on or about 01/20/2026 on Nasdaq. The planned sale has an indicated aggregate market value of $6,330,000. The seller acquired the 200,000 shares from the issuer on the same date via a stock option exercise paid in cash. The filing also lists 113,390,804 ordinary shares outstanding for the issuer, providing context for the size of this planned transaction.
NewAmsterdam Pharma Co N.V. director Hilde Johanna van der Kamp reported new equity awards. On January 7, 2026, she received 3,400 restricted stock units (RSUs), each representing one ordinary share, granted for no consideration and scheduled to vest in full on the one-year anniversary of the vesting start date, subject to continued service. She also received an option to buy 15,300 ordinary shares at an exercise price of $35.45 per share, with all option shares vesting on January 2, 2027, also conditioned on continued service.
NewAmsterdam Pharma Co. N.V. director Adele M. Gulfo reported equity awards in the form of ordinary shares and options. On January 7, 2026, she received 3,400 restricted stock units (RSUs), each representing one ordinary share, bringing her directly held ordinary shares to 14,260. The RSUs were granted for no cash consideration and will fully vest on the one-year anniversary of the vesting start date, subject to her continued service.
On the same date, she was also granted an option to purchase 15,300 ordinary shares at an exercise price of $35.45 per share, with 15,300 options owned following the grant. All shares underlying the option are scheduled to vest on January 2, 2027, also conditioned on her continued service.
NewAmsterdam Pharma Co N.V.'s Chief Executive Officer and director Michael H. Davidson reported several equity transactions dated January 7, 2026. He sold 11,582 ordinary shares in a pre-arranged sell-to-cover transaction used solely to satisfy tax withholding on vesting restricted stock units, at a weighted average price between $35.24 and $35.59 per share. After this sale, he directly owned 378,859 ordinary shares.
On the same date, he acquired 81,000 restricted stock units (RSUs), each representing one ordinary share. These RSUs were granted for no consideration and are scheduled to vest in three equal annual installments on the first, second and third anniversaries of the vesting start date, contingent on his continued service. He was also granted an option to buy 364,000 ordinary shares at an exercise price of $35.45 per share, expiring on January 7, 2036, with 25% vesting on January 2, 2027 and the remainder vesting monthly over the following three years, subject to continued service.
NewAmsterdam Pharma Co. N.V. director William Lewis reported equity awards from the company. On January 7, 2026, he received 3,400 restricted stock units (RSUs), each representing a contingent right to one ordinary share, granted for no cash consideration. All of these RSUs will vest on the one-year anniversary of the vesting start date, subject to his continued service.
On the same date, he was also granted an option to buy 15,300 ordinary shares, with all underlying shares scheduled to vest on January 2, 2027, also conditioned on continued service. Following the RSU grant, Lewis beneficially owned 10,360 ordinary shares directly.
NewAmsterdam Pharma Co. N.V. director John W. Smither reported equity compensation awards. On January 7, 2026, he received 3,400 restricted stock units (RSUs), each representing one ordinary share, granted for no consideration. All RSUs will vest on the one-year anniversary of the vesting start date, subject to his continued service.
On the same date, he was also granted an option to buy 15,300 ordinary shares at an exercise price of $35.45 per share. These option shares will vest on January 2, 2027, the one-year anniversary of the vesting start date, if he continues in service. After these transactions, he directly owns 10,360 ordinary shares and 15,300 options.
NewAmsterdam Pharma Co. N.V. reported that director Mark C. McKenna received new equity awards. On January 7, 2026, he was granted 3,400 restricted stock units (RSUs), each representing the right to receive one ordinary share. These RSUs will vest in full on the one-year anniversary of the vesting start date, conditioned on his continued service. They were granted for no cash consideration, and following this award he beneficially owns 10,360 ordinary shares directly.
On the same date, McKenna also received an option to acquire 15,300 ordinary shares at an exercise price of $35.45 per share, expiring on January 7, 2036. All shares underlying this option will vest on January 2, 2027, also subject to his continued service, leaving him with 15,300 derivative securities beneficially owned.
NewAmsterdam Pharma Co N.V. director Louis G. Lange reported equity awards granted on January 7, 2026. He received 3,400 restricted stock units, each representing a contingent right to one ordinary share, granted for no consideration and scheduled to vest on the one-year anniversary of the vesting start date, subject to his continued service.
On the same date, he was granted an option to purchase 15,300 ordinary shares at an exercise price of $35.45 per share. All shares underlying this option are scheduled to vest on January 2, 2027, also contingent on continued service. Following these awards, he beneficially owned 10,360 ordinary shares and 15,300 options directly.